Shook Partner Matt Keenan and Of Counsel John F. Johnson III will be speaking as part of the Food and Drug Law Institute’s (FDLI) all-virtual Advertising and Promotion for Medical Products Conference, October 28-30. This year’s virtual conference will enable a new level of interaction between regulatory practitioners, industry experts and government officials, which will include representatives from various FDA Centers, Federal Trade Commission, Department of Health and Human Services Inspector General and Department of Justice.
Johnson will be moderating the breakout session, “Practical Considerations for Successful Remote-Based Marketing Strategies,” October 28, 12:00-12:45 p.m. CDT. This session will provide discussion of successful remote-based marketing strategies and updated compliance programs, including sharing experiences through polling and Q & A. Topics include sales team outreach through phone, email, text, separation of scientific/commercial virtual booths, sponsorships, speaker programs and remote training of health care and office personnel.
Keenan will be moderating “Case Study: Best Practices in Drug Sales and Marketing,” October 30, 12:55–1:55 p.m. CDT. This drug-focused case study will explore a fictional company that encounters post-approval adverse events, leading to several label changes and a competing drug with a lower risk profile. These events will lead to litigation and other resulting complications. The study will use mock video clips to assist in identifying issues that could have been avoided or mitigated.
Keenan is a pharmaceutical and medical device attorney who works on national product liability cases. He has prepared and defended 51 company witnesses for depositions in five MDL proceedings over the past 30 years. Johnson counsels and represents clients in the pharmaceutical and medical device and food, beverage and agribusiness industries, working with manufacturers, distributors, brand owners, importers and retailers of food, drugs, medical devices, cosmetics and animal products, to satisfy their regulatory obligations.